Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 1

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
     (73,175,649) 
     (60,439,183)

    Total stockholders’ equity 
     4,605,727  
     3,944,875 

    Total liabilities and stockholders’ equity 
    $6,840,052  
    $7,338,756 

    *
    Retroactively
    restated for one-for-twenty-eight share consolidation on June 27, 2025.

See
accompanying notes to the unaudited condensed consolidated financial statements

F-1

INDAPTUS
THERAPEUTICS, INC.

Unaudited
Condensed Consolidated Statements of Operations

    2025  
    2024  
    2025  
    2024 

    Three Months Ended September 30,  
    Nine Months Ended September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Operating expenses: 

    Research and development 
    $1,517,723  
    $1,466,037  
    $6,495,677  
    $4,771,152 
  
    General and administrative 
     1,130,764  
     1,676,020  
     5,182,132  
     6,423,029 

    Total operating expenses 
     2,648,487  
     3,142,057  
     11,677,809  
     11,194,181 

    Loss from operations 
     (2,648,487) 
     (3,142,057) 
     (11,677,809)  
     (11,194,181)

    Other income, net 
     39,088  
     73,021  
     94,764  
     303,201 
  
    Change in fair value of convertible promissory notes 
     (365,718) 
     -  
     (1,153,421) 
     - 

    Net loss 
    $(2,975,117) 
    $(3,069,036) 
    $(12,736,466) 
    $(10,890,980)

    Net loss available to common stockholders per share of common stock, basic and